55 F.4th 1368
Fed. Cir.2022Background
- Pirfenidone (Esbriet®) treats idiopathic pulmonary fibrosis (IPF); Genentech holds method patents (LFT and DDI patents) that claim dose-modification methods for managing pirfenidone side effects, not the drug or its use to treat IPF itself.
- Sandoz filed ANDAs for a generic pirfenidone, including proposed label language addressing elevated liver enzymes (ALT/AST) and interactions with strong CYP1A2 inhibitor fluvoxamine.
- Genentech sued under Hatch–Waxman, asserting the ANDA would induce infringement of LFT patents (methods for managing Grade 2 liver-enzyme elevations) and DDI patents (methods for avoiding pirfenidone–fluvoxamine interactions).
- District court found asserted LFT claims obvious over Azuma (a pirfenidone trial), the Japanese Pirespa® label, and standard medical practices, and found no induced infringement because the label merely described, not recommended, infringing uses.
- For the DDI patents, the district court found insufficient evidence of direct infringement (uncertainty that both drugs would be prescribed together and that physicians would follow claimed methods) and thus did not reach inducement intent.
- Federal Circuit affirmed: LFT claims obvious; no clear error in finding no direct infringement of DDI claims; therefore affirmed judgment for Sandoz.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Obviousness of LFT claims | Genentech: Azuma and Pirespa® do not disclose Grade 2 elevations or claimed continued-treatment regimens; objective indicia support nonobviousness | Sandoz: Azuma + Pirespa® + standard medical practice taught dose reduction, interruption, and reescalation for adverse events | Court: Claims obvious over Azuma, Pirespa®, and routine medical practice; objective indicia insufficient to overcome prima facie case |
| Induced infringement of LFT patents | Genentech: Sandoz label recommends dose modifications that match claimed methods, showing specific intent to induce | Sandoz: Label only describes options; no specific intent and no showing the label will lead to infringement | Court: No specific intent; label language descriptive, not a recommendation of infringing uses (no induced infringement) |
| Direct infringement of DDI patents | Genentech: Label instructs discontinuing fluvoxamine or reducing pirfenidone to 801 mg/day — this directs the claimed methods | Sandoz: Physician practice and evidence show concomitant prescribing is unlikely; label alone insufficient to prove method use will occur | Court: Patentee failed to show by preponderance that marketed product would be used to perform claimed methods; no clear error in weighing label against physician practice; no direct infringement |
| Inducement of DDI patents (intent) | Genentech: If direct infringement exists, label guidance shows Sandoz had specific intent to induce | Sandoz: No predicate direct infringement; intent issue not reached | Court: Did not reach inducement because direct infringement not proven |
Key Cases Cited
- Grunenthal GMBH v. Alkem Lab’ys Ltd., 919 F.3d 1333 (Fed. Cir. 2019) (standard of review for bench-trial factual findings)
- Vanda Pharms. Inc. v. W.-Ward Pharms. Int’l Ltd., 887 F.3d 1117 (Fed. Cir. 2018) (Hatch–Waxman induced-infringement standards and label-based intent analysis)
- Takeda Pharms. U.S.A., Inc. v. W.-Ward Pharms. Corp., 785 F.3d 625 (Fed. Cir. 2015) (consideration of extrinsic evidence and physician practice when assessing direct infringement)
- Hospira, Inc. v. Fresenius Kabi USA, LLC, 946 F.3d 1322 (Fed. Cir. 2019) (obviousness legal framework: law reviewed de novo; facts for clear error)
- Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 25 F.4th 1354 (Fed. Cir. 2022) (scope and content of prior art as factual findings reviewed for clear error)
- Ferring B.V. v. Watson Labs., 764 F.3d 1401 (Fed. Cir. 2014) (must consider all relevant evidence — label and physician practice — when predicting how an ANDA product will be used)
- Glaxo, Inc. v. Novopharm, Ltd., 110 F.3d 1562 (Fed. Cir. 1997) (ANDA filing is an act of infringement under §271(e)(2) but does not relieve patentee of proving infringement)
- Eli Lilly & Co. v. Teva Parenteral Meds., Inc., 845 F.3d 1357 (Fed. Cir. 2017) (label plus physician-practice evidence can establish likelihood of direct infringement)